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Abstract  
Background: Whole-gland salvage Iodine-125-brachytherapy is a potentially curative treatment 
strategy for localised prostate cancer (PCa) recurrences after radiotherapy. Prognostic factors 
influencing PCa-specific and overall survival (PCaSS & OS) are not known. The objective of this study 
was to develop a multivariable, internally validated prognostic model for survival after whole-gland 
salvage I-125-brachytherapy.    
Materials and methods: Whole-gland salvage I-125-brachytherapy patients treated in the 
Netherlands from 1993-2010 were included. Eligible patients had a transrectal ultrasound-guided 
biopsy-confirmed localised recurrence after biochemical failure (clinical judgement, ASTRO or 
Phoenix-definition). Recurrences were assessed clinically and with CT and/or MRI. Metastases were 
excluded using CT/MRI and technetium-99m scintigraphy. Multivariable Cox-regression was used to 
assess the predictive value of clinical characteristics in relation to PCa-specific and overall mortality. 
PCa-specific mortality was defined as patients dying with distant metastases present. Missing data 
was handled using multiple imputation (20 imputed sets). Internal validation was performed and the 
C-statistic calculated. Calibration plots were created to visually assess the goodness-of-fit of the final 
model. Optimism-corrected survival proportions were calculated. All analyses were performed 
according to the TRIPOD statement. 
Results: Median total follow-up was 78 months (range 5-139). A total of 62 patients were treated, of 
which 28 (45%) died from PCa after mean (±SD) 82 (±36) months. Overall, 36 patients (58%) patients 
died after mean 84 (±40) months. PSA doubling time (PSADT) remained a predictive factor for both 
types of mortality (PCa-specific and overall): corrected hazard ratio’s (HR’s) 0.92 (95%-CI: 0.86-0.98, 
p=0.02) and 0.94 (95%-CI: 0.90-0.99, p=0.01), respectively (C-statistics 0.71 and 0.69, respectively). 
Calibration was accurate up to 96 months follow-up. Over 80% of patients can survive 8 years if 
PSADT>24 months (PCaSS) and >33 months (OS). Only approximately 50% survival is achieved with a 
PSADT of 12 months. 
Conclusion: A PSADT of respectively >24 months and >33 months can result in >80% probability of 
PCa- specific and overall survival 8 years after whole-gland salvage I-125-brachytherapy. Survival 
should be weighed against toxicity from a salvage procedure. Larger series and external validation 
are necessary. 
Introduction  
Brachytherapy and external beam radiotherapy (EBRT) can achieve high tumour control in patients 
with primary prostate cancer1,2. EBRT dose escalation has led to further improvement of these 
results1,3. However, depending on tumour characteristics, PSA-parameters and use of androgen 
deprivation therapy (ADT), biochemical recurrences can still occur in 30-50% of patients after 5-10-
years1,3. Over 80% of patients can harbour a prostate-only recurrence4. Local salvage therapy is a 
potentially curative treatment for these prostate-confined recurrences. Whole-gland salvage can be 
performed using different techniques and is able to achieve long term biochemical control and 
survival and thereby postpone the use of androgen deprivation therapy (ADT) in carefully selected 
patient groups5-9.  
Risk factors for failure and mortality for salvage brachytherapy have not been comprehensively 
defined, because of small series with often limited events5,9,10. A few series have defined pre-salvage 
PSA, PSA-doubling time (PSADT) and time-to-relapse after primary therapy as possible predictors of 
biochemical failure after salvage brachytherapy11-13. Although biochemical failure often precedes the 
development of distant metastases and death1, no predictive factors for survival have as of yet been 
identified. In this report, we therefore aimed to develop a prognostic model for PCa-specific survival 
(PCaSS) and overall survival (OS) after whole-gland salvage 125-brachytherapy, based on the largest 
salvage I-125-brachytherapy cohort. 
Materials and Methods 
Patient selection, data collection and outcome assessment 
 
The institutional review board of the University Medical Center Utrecht (UMCU) permitted the 
analysis of the data. In total, 62 patients were treated with whole-gland salvage I-125-brachytherapy 
from November 1993 until April 2010 in both the University Medical Center, Utrecht (n=33) and the 
Radiotherapeutic institute RISO, Deventer, the Netherlands (n=29). Selection was based on objective 
assessment of a localised recurrence after biochemical failure (according to clinical judgement and 
the ASTRO or Phoenix definition after 1996 and 2005, respectively). Localised disease was transrectal 
ultrasound-guided biopsy-confirmed, with absence of lymph node or distant metastases based on 
pelvic CT and/or MRI (n=22) and technetium-99m scintigraphy (bone-scan). Transrectal ultrasound 
(in all patients) or MRI (in 22 patients) was used to exclude capsular extension. PSA, PSA-kinetics and 
other prognostic factors before primary therapy and salvage were not used for selection and were 
judged by the treating radiation oncologist. ADT was discontinued at salvage. 
Survival data was obtained by the primary researcher (MP) from patient charts. Survival was 
subdivided in prostate cancer specific survival (PCaSS) and overall survival (OS) after salvage 
brachytherapy. PCaSS was separately evaluated using the records by two independent radiation 
oncologists (JVZ, CH). For death due to prostate cancer, it was necessary to have distant metastases.  
Toxicity 
Late (>6 months post-implantation) severe (≥ grade 3) gastrointestinal (GI) and genitourinary (GU) 
toxicity was evaluated with the common terminology criteria for adverse events (CTCAE 4.03). 
Implantation details 
The prescription for the prostatic V100 (volume of the prostate receiving 100% dose [=145 Gy]) was 
≥95%. The D90 (minimal dose received by 90% of the prostate) was ≥145 Gy. In the UMCU images 
were imported in the Sonographic Planning of Oncology Treatment planning software (SPOT, 
Nucletron BV, Veenendaal, the Netherlands). The planning system in the RISO consisted of 
subsequent versions of VariseedTM (Varian Medical Systems, Palo Alto, CA). Loose and stranded seeds 
were both used in this cohort.  
Analysed predictive factors  
 
Factors before primary radiotherapy consisted of primary treatment (Iodine-125 brachytherapy or 
EBRT/IMRT), dose (>64.4 Gy or ≤64.4Gy), initial PSA (iPSA), T stage (1, 2 or 3) and initial Gleason 
grade (2-6, 7, or 8-10). Sub-classification of T-stage was frequently missing, so only the overall T-
stage was used. Factors before salvage brachytherapy were PSA-nadir (i.e. the lowest PSA-value) 
after primary treatment, (biochemical) disease free survival interval (DFSI) after primary 
radiotherapy, age, PSA, PSADT, PSA-density (=PSA-value divided by the prostatic volume as assessed 
on ultrasound), PSA-velocity and ADT-use. Gleason score pre-salvage was not analysed because of 
the chance of misclassification due to radiation effects (and therefore frequently missing scores)14. 
PSA kinetics (PSA-velocity and PSADT) were calculated using the Memorial Sloan Kettering Cancer 
Center calculator15.  
PSA-nadir after salvage was separately analysed, because of its redundancy in patient selection. No 
interactions between variables were considered. 
Statistical analysis 
Normally distributed variables are presented as mean (±SD), skewed distributed variables as medians 
with ranges, and categorical data as frequencies with percentages. Kaplan-Meier survival analyses for 
PCaSS and OS were performed for categories of possible predictor variables. Categories of predictors 
were based on common prognostic categories from the literature (e.g. PSA ≤10 and >10 ng/ml and 
PSADT≤ 10 months and >10 months16). Receiver operating characteristic (ROC)-analysis was 
performed for PSA-density and PSA-velocity to identify cutoff values with maximal sensitivity and 
specificity, since groups were unequal when categories based on the literature were adopted. 
Differences were tested with the log-rank test.  
Missing data was considered at random. Multiple imputation (MI) with the iterative Markov Chain 
Monte Carlo method was performed (20 iterations)17,18. The MI-procedure was performed with all 
predictors listed above in the imputation process, including the outcome (PCaSS and OS)18,19.  
 
Model building 
 
Univariable and multivariable Cox-proportional hazards regression was performed. Before Cox-
regression, correlation coefficients between PSA, PSA kinetic factors and other predictors were 
calculated. Pearson’s correlation coefficient was used in case of linear relations and Spearman’s rank 
correlation in case of a non-linear correlation. Factors were excluded from multivariable analysis 
when collinearity was present (i.e. correlation coefficient ≥0.75). When (multi)collinearity was 
present, the factor measurable with the least practical effort was given priority to aid clinical 
application. From univariable analysis, factors were selected for multivariable analysis if p<0.10 
based on the Wald-test. Stepwise backward elimination was used for the multivariable analysis and 
the models were compared at each step with the likelihood ratio test statistic. Proportional hazards 
was visually evaluated with log-log curves for categorical predictors and Schoenfeld residuals for 
continuous variables. Survival proportions were calculated with (S(t)=S(0)exp(βpredictor1*predictor1 + 
βpredictor2*predictor2 etc.)). The β’s are the natural logarithm of the hazard ratio’s from multivariable analysis. 
S(0) is the baseline survival proportion at a specified follow-up point with determinants from 
multivariable analysis equaling 0. No correction for multiple testing was performed since parameters 
were often highly correlated with one another, thereby possibly inducing type II errors when 
conservatively adjusting the α-level.  
 
Internal validation and calibration 
 
Harrell’s C-statistic (concordance index) was used as a discrimination measure, comparable to an 
area-under-the-curve (AUC) value from logistic regression20. With 500 bootstrapping resamples for 
each of the 20 imputed datasets, the optimism of the model and shrinkage factor for the coefficients 
were calculated, after which the C-statistic and coefficients (and subsequently HR’s) could be 
adjusted. 
The predictive accuracy for PCaSS and OS was visualised with calibration plots at 5 and 8-years. No 
external validation could be performed. Kaplan-Meier survival analysis, MI and Cox-proportional 
hazards regression procedures were performed using IBM SPSS version 20 (statistical package for the 
social sciences Inc, Chicago, IL). R language environment (version 3.1.2) for statistical computing 
(available at http://www.r-project.org/21) was used for calibration and internal validation (survival 
and rms package). Statistical significance was set at p ≤0.05. All procedures and reporting were based 
on the transparent reporting of multivariable prediction models for individual prognosis or diagnosis 
(TRIPOD) statement22.    
 
Results 
Patient characteristics  
Primary radiotherapy consisted of 64.4 Gy in 23 fractions of 2.3 Gy in the majority of patients (n=26, 
45%). Most patients had favourable tumor characteristics before primary radiotherapy and salvage, 
although outliers were present (e.g. PSA before salvage was 92.6 ng/ml in one patient, with the 
second highest 25.5 ng/ml) (Table 1). Response to salvage was present in 51 (82%) of 62 patients. 
Median total follow-up was 78 months (range 5-139). In total, 36 patients (58%) patients died during 
follow-up. The mean time to death was 84 (±40) months. Twenty-eight (45%) patients died due to 
PCa after 82 (±36) months. Eight patients died unrelated to the PCa, six of whom did not experience 
biochemical failure.  
Toxicity 
Data to assess GI and GU toxicity was available for 60 and 61 patients, respectively. A total of 12 
patients (20%) experienced radiation proctitis for which they were treated with argon plasma laser 
coagulation. Late ≥grade 3 GU toxicity was present in 18 patients (30%). Urethral strictures (n=10) 
and urinary retention (n=4) were most frequently observed. Finally, 5 patients (8%) were observed 
with a combined toxicity profile with both GI and GU toxicity: two patients had a grade 3 and one 
patient a grade 4 rectovesical fistula. Lastly, two patients experienced a grade 3 rectourethral fistula.          
Kaplan-Meier survival analysis 
The 10-year estimated PCaSS was 43%, with median survival of 108 months (95% CI: 91-125). After 
10-years, OS was 34%, with a median survival of 104 months (95% CI: 94-115).  
Patients with a pre-salvage PSA ≤10 ng/ml had 10-year PCaSS of 65% versus 15% for patients with 
PSA>10 ng/ml (log rank: p<0.0001). OS also differed, with 10-year OS being 53% versus 12%, 
respectively (p<0.0001). Patients with a PSADT >10 months compared to ≤10 months had a 10-year 
PCaSS of 71% versus 22%, (p=0.002), and an OS of 47% versus 21% (p=0.03), respectively. Other 
prognostic variables significantly associated with decreased PCaSS and OS were DFSI<36 months, 
PSA-density>0.25 ng/ml/cc, PSA-velocity>3ng/ml/year and nadir after salvage>1.0 ng/ml. Primary 
patient and tumor characteristics were not associated with survival after salvage. Primary Gleason 8-
10 tumours were almost significantly related to survival compared to Gleason 2-6 and 7, but the 
group consisted of only 3 cases. Kaplan-Meier results are depicted in Table 2 and supplementary 
figures. 
Missing data 
No outcome data was missing. Predictor variables not standardised in follow-up had the most 
missing values (PSA-velocity and DFSI, both 11 [17.7%]). There was significant overlap in missing 
data, with approximately 80% of cases having no missing values. Because of no intrinsic relation with 
the missing values or the outcomes, data was considered missing at random. Table 1 lists further 
information on missing data.  
Correlation 
Pre-salvage PSA and PSA-density showed the highest correlation (Pearson correlation coefficient 
0.95, p<10-29). Pre-salvage PSA and PSA-velocity were also highly correlated (Spearman’s rank 
correlation 0.8, p<10-11). All other significant correlations were <0.75. The largest of these correlation 
was between pre-salvage PSA and DFSI (Spearman: -0.65, p<10-6), DFSI and PSADT (Pearson: 0.58, 
p<0.0001) and between PSA and nadir-after salvage (Spearman: 0.51, p<0.001). Due to these 
correlations, PSA-density and PSA-velocity were excluded from the multivariable Cox-regression 
analysis. PSA was kept in, because it consists of only a single measurement.  
 
Modelling results, internal validation and calibration 
Univariable analysis showed PSA, PSADT, PSA-velocity and PSA-nadir after salvage as significant 
predictors for PCaSS and OS. For PCaSS, PSA-density and DFSI were almost significant (p=0.06 and 
p=0.054). For OS, significance of DFSI disappeared (p=0.13). Univariable, ADT use was almost 
significant for OS (p=0.08). After multivariable analysis for PCaSS (variables included: DFSI, PSA and 
PSADT), only PSADT remained as a significant predictor: corrected hazard ratio (HR) 0.92 (95%-CI: 
0.86-0.98, p=0.02), indicating an approximate 8% decrease in hazard for PCaSS for each month 
increase in PSADT. PSADT remained a significant predictor for OS after multivariable analysis 
(variables included: ADT, PSA and PSADT): corrected HR 0.94 (95%-CI: 0.90-0.99, p=0.01), respectively 
(Table 3). There were no violations of the proportional hazards assumption. The apparent C-statistic 
was 0.73 for PCaSS 0.71 for OS and adjusted 0.71 and 0.69, respectively. Shrinkage factors were 0.77 
for PCaSS and 0.71 for OS. Calibration plots after 5 and 8 years are depicted in Figure 1. Observed 
survival frequencies are concordant with predicted probabilities from the final models up to 8 years.  
Survival proportions 
Baseline cumulative survival proportions (S(0)) for PCaSS and OS at 8 years were 0.215 and 0.219, 
respectively. In patients with a pre-salvage PSADT>24 months, whole-gland salvage I-125-
brachytherapy results in a >80% chance of PCaSS up to 8 years. For OS, a PSADT >33 months results 
in this survival percentage (Figure 2 and supplementary table 4). With a PSADT of 12 months or 
lower, survival dropped to approximately ≤50%.  
Discussion 
In summary, our study has shown a relation with several pre-salvage characteristics and both 
prostate cancer specific and overall survival after whole-gland salvage I-125-brachytherapy for 
localised prostate cancer recurrences after primary radiotherapy. After multivariable Cox analysis, 
only PSADT remained a predictor of both PCaSS and OS: corrected hazard ratio (HR) 0.92 (95%-CI: 
0.86-0.98, p=0.02) and 0.94 (95%-CI: 0.90-0.99, p=0.01), respectively. This implies a decrease in 
hazard for mortality of approximately 8% and 6% with every month increase in PSADT, respectively.  
To our knowledge these 62 patients constitute the largest whole-gland salvage I-125-brachytherapy 
series, with sufficient events for prognostic modelling. We have used the recent TRIPOD statement 
regarding the conduct and reporting of prognostic research22, to ensure transparent reporting of 
handling variables, missing data, model building, validation and calibration. We trust this might 
facilitate comparison with future groups reporting on salvage I-125-brachytherapy outcomes. For 
now, with the optimism-corrected hazard ratio’s for PSADT and baseline survival proportion, exact 
survival percentages can be calculated in clinical practice for individual patients.  
Nonetheless, our study has some limitations. At 8 years, calibration was decent for both PCaSS and 
OS, although with a relatively large spread as is visible in the wide confidence intervals of the 
observed (Kaplan-Meier) survival estimates. The same is applicable to the predicted survival 
probabilities. Larger groups and possibly other predictors are necessary to add precision to the 
current estimates. 
It is possible that factors not taken into account for this analysis, such as pre-salvage Gleason grade8 
and morphological findings on MRI (and/or functional sequences), might have additional predictive 
ability for progression and survival. These were not available in the current patient cohort. 
Furthermore, a type I error in one/some of the assessed parameters is a possibility due to multiple 
testing. However, parameters were often (highly) correlated with one another, thereby reducing the 
risk of a type I error. Also, correcting the α-level conservatively with a Bonferroni, Šídák or Holm’s 
Sequential Bonferroni procedure would assume independence of the separate tests and therefore 
automatically increase the chance of a type II error (i.e. incorrect non-significant results). 
Furthermore, PSADT had a significant relation with both types of mortality, making a type I error less 
likely (even though both types of mortality show overlap). Lastly, an explorative approach was 
adopted for this set of clinical variables, since this database is the largest nowadays for whole-gland 
salvage I-125-brachytherapy. This could provide valuable insight into which variables are important 
for future research into the topic. They do have to be verified in other series, however.  
Interestingly, factors before primary radiotherapy do not show an effect on survival. Selection of 
salvage patients is often performed based on these characteristics16,23. These findings could be an 
indication of their relative insignificance for patient selection. Contrary to this hypothesis, Gleason 8-
10 before primary radiotherapy consisted of only 3 patients and showed a tendency in the Kaplan-
Meier analysis to low survival. The prognostic relevance of this factor could have been 
underestimated in our analysis. Quantification can be provided when larger numbers are assessable.  
Lastly, without external validation this model cannot provide clinically robust estimates of predicted 
survival. External validation could decrease the predictive accuracy of PSADT as found in this 
population, since the current cohort consisted of a relatively dated and high risk population. This 
uncertainty needs to be taken into account when selecting whole-gland salvage I-125-brachytherapy 
patients based on their PSADT. However, as this is the only predictive factor from extensive 
multivariable analysis in predicting survival after whole-gland salvage prostate I-125-brachytherapy 
so far, it could provide additional guidance in the selection of patients in clinical practice or to 
intensify post-salvage follow-up in patients deemed at high risk for treatment failure and mortality. 
Patients with a PSADT <20 months require at least additional follow-up after salvage to assess 
disease progression or salvage should be offered earlier or perhaps not at all. Furthermore, the 
benefits of treatment regarding cancer control/survival need to be weighed against the exacerbated 
toxicity after whole-gland salvage I-125-brachytherapy, as was observed in this and previous series5,6.  
 
Other series have provided risk factors for biochemical failure with small groups of whole-gland 
salvage LDR I-125/Pd-103 and HDR Ir-192-brachytherapy patients and even focal salvage approaches 
(directed locally at the recurrence)10-13,24-30. Only a few of the whole-gland salvage brachytherapy 
studies provide multivariable modelling, with often limited events, categorisation of predictor 
variables and insufficient description of handling missing data, leading to imprecise estimates11-13,26. 
However, there is no data on predictive factors for survival (PCaSS and OS). Predictive factors for 
survival in other salvage modalities (such as radical prostatectomy and cryosurgery) are more 
comprehensively defined, because of larger patient numbers and longer follow-up7,8. These factors 
(PSA pre-salvage, primary Gleason score, T-stage [both only univariable] and nadir after salvage, 
among other) are possibly important for salvage brachytherapy as well, but are not quantified in this 
setting with multivariable models.  
In addition, although biochemical failure often precedes the development of distant metastases and 
(PCa-specific) mortality1, it is unclear whether predictive factors associated with biochemical failure 
can be extrapolated to mortality in the case of salvage brachytherapy patients. Due to often more 
advanced age at salvage, it is questionable whether these factors will also predict survival in the 
same manner. Therefore, this analysis has provided the first identification of a pre-savage 
characteristic which can predict both types of survival in whole-gland salvage I-125-brachytherapy. 
The PSADT could be used to select patients or identify patient with a poor response to salvage and 
subsequently intensify follow-up or reject further salvage. The toxicity from such a procedure should 
be taken into account with this consideration as well.    
 
Conclusion 
PSADT is the only predictive factor for survival after whole-gland salvage I-125-brachytherapy. More 
than 80% survival can be achieved with PSADT>24 months (PCaSS) and >33 months (OS) up to 8 years 
after salvage. Only approximately 50% survival is achieved with a PSADT of 12 months and therefore, 
survival should be weighed against potential toxicity from a salvage procedure. Larger series, other 
predictive factors and external validation are warranted.  
Take home message: 
PSA-doubling time is the first parameter to predict survival after whole-gland salvage Iodine-125-
brachytherapy. Over 80% prostate cancer specific and overall survival can be achieved with 
PSADT>24 months and >33 months up to 8 years after salvage. 
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